FINDING OF NO SIGNIFICANT IMPACT

Marketing Orders for

Elements Rolls Ultra Thin SW, Elements Rolls Ultra Thin 1¼, Elements Rolls Ultra Thin 1½ KS, Elements Refills SW, Elements Refills 1¼, and Elements King Size

Manufactured by

BBK Tobacco & Foods, LLP Company dba HBI International

The Center for Tobacco Products of the Food and Drug Administration (FDA) has carefully considered the potential environmental impacts of these actions and has concluded that these actions will not have significant effects on the quality of the human environment. Therefore, environmental impact statements are not required.

BBK Tobacco & Foods, LLP Company dba HBI International wishes to introduce six new roll-your-own (RYO) rolling papers into interstate commerce for commercial distribution in the United States and submitted to FDA six substantial equivalence reports to obtain marketing orders under the provisions of sections 910 and 905(j) of the Federal Food, Drug, and Cosmetic Act.

The Agency prepared the programmatic environmental assessment (PEA), dated August 6, 2020, in accordance with the Council on Environmental Quality's regulations (40 CFR Part 1500–15800) implementing the National Environmental Policy Act (NEPA) and FDA’s NEPA regulations (21 CFR 25.40) to support the finding of no significant impact. The evidence supporting these findings is contained in the attached PEA, which is available to the public upon request.

The PEA evaluates potential environmental effects due to manufacturing, use, and disposal of the new products. No increased or new types of environmental impacts due to manufacturing the new products are anticipated. The Agency does not foresee that use of the new products would result in new or different environmental impacts. The Agency believes that the disposal of the new tobacco products would be the same as the disposal conditions of other RYO products that are currently marketed in the United States. Therefore, the Agency does not foresee adverse impacts to the environment due to the proposed action as a result of manufacturing, use, and disposal of the new products.

Approved by

Luis Valerio Jr., PhD, ATS
Associate Director
Division of Nonclinical Science
Office of Science
Center for Tobacco Products
U.S. Food and Drug Administration

Digitally signed by Luis G. Valerio -S
Date: 2020.08.06 23:06:55 -04'00'